Hamps Bio Ltd.

Date: November 06, 2026

To,
The Manager
BSE Limited
1st Floor, New Trading Ring,
Phiroze Jeejeebhoy Towers, Dalal Street,
Fort,
Mumbai 400001 (Maharashtra)
Scrip Code: 544312

Subject: Outcome of the Board Meeting of HAMPS BIO LIMITED held on Friday, November 06, 2026, pursuant to the Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir/ Madam,

Pursuant to the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you, that the Board of Directors of the Company at its meeting held on today, Friday, November 06, 2026, at the registered Office of the Company situated at Plot No C1 -B -106, Nr - Mama Bhanja Factory Bhatpore GIDC, Bhatpore, Surat, Choryasi, Gujarat, India, 394510, has inter-aila discussed and approved the following business:

1. Considered and approved the Unaudited Standalone and consolidated Financial Results along with Limited review report for the half year ended 30.09.2026 and the same is attached herewith.

The Board Meeting commenced at 4:00 P.M (IST) and concluded at 7:00 P.M. (IST).

You are kindly requested to take the above on your record and update the same.

Yours faithfully,
For HAMPS BIO LIMITED

RAVI BAHETI
Digitally signed by RAVI BAHETI
Date: 2026.11.06 19:54:43 +05'30'

Ravi Baheti
Company Secretary
Membership No.: A49472
Enclosure: As above

CIN No. : L24233GJ2007PLC049692
Factory : Unit - 1 : 2900/112, G.I.D.C., Industrial Estate, Nr. Atul Ltd., Ankleshwar-393002
Corporate & Register : Plot No. C1-B-106, Nr-Mama Bhanja Fcatory, Bhatpore G.I.D.C.,
Office address Surat, gujarat, India-394510
E-mail : hamps.bio@gmail.com, Web : www.hampsbio.com, Mo.No. : 8000001113, 8000006663

MGHVS & ASSOCIATES
Chartered Accountants
8154912316, 9265096979
7048388605, 9737211161
802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

Independent Auditors' Review Report on Standalone Unaudited Half Yearly Financial Results of the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To
The Board of Directors,
M/s. HAMPS BIO LIMITED

Opinion

We have reviewed the accompanying statement of Standalone Unaudited Financial results ("the statement) of **M/s. HAMPS BIO LIMITED** (the company) for the **Half year ended 30th September, 2026** being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").


This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors AND has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

MGHVS & ASSOCIATES
Chartered Accountants
8154912316, 9265096979
7048388605, 9737211161
802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

Based on our limited review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with Accounting Standard and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M G H V S & ASSOCIATES
Chartered Accountants



CA MUBASSIR M GODIL
(Partner)
M. No: 164503
FRN: 140555W
Place: Surat
Date: 06/11/2026
UDIN: 26164503FGIGAH4772

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

(CIN: L24233GJ2007PLC049692)

(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)

Standalone Statement of Balance Sheet as at 30th September, 2026

Particulars	30 September 2026	31 March 2026
I. EQUITY AND LIABILITIES		
(1) Shareholders' funds		
(a) Share Capital	871.20	871.20
(b) Reserves and Surplus	(32.97)	(52.73)
Total	838.23	818.47
(2) Non-current liabilities		
(a) Long-term Borrowings	418.08	376.36
(b) Other Long-term Liabilities	10.35	10.21
Total	428.43	386.57
(3) Current liabilities		
(a) Short-term Borrowings	156.85	263.58
(b) Trade Payables	-	-
- Due to Micro and Small Enterprises	-	7.45
- Due to Others	41.57	26.12
(c) Other Current Liabilities	44.10	18.86
(d) Short-term Provisions	2.94	1.30
Total	245.46	317.31
Total Equity and Liabilities	1,512.11	1,522.35
II. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	784.62	698.92
(ii) Intangible Assets	21.43	19.91
(iii) Capital Work-in-progress	-	108.37
(iv) Intangible Assets under Development	-	-
(b) Non-current Investments	204.11	204.11
(c) Deferred Tax Assets (net)	1.68	3.41
(d) Other Non-current Assets	24.58	25.85
Total	1,036.42	1,060.56
(2) Current assets		
(a) Inventories	229.87	244.28
(b) Trade Receivables	149.90	120.56
(c) Cash and cash equivalents	7.89	3.45
(d) Short-term Loans and Advances	-	-
(e) Other Current Assets	88.03	93.50
Total	475.69	461.78
Total Assets	1,512.11	1,522.35

See accompanying notes to the financial statements

As per our report of even date

For and on behalf of the Board of

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

FOR, HAMPS BIO LIMITED

HERRIK SHAH DIRECTOR

MANAGING DIRECTOR

01052316

FOR, HAMPS BIO LIMITED

SHRENIK SHAH

DIRECTOR

WHOLE TIME DIRECTOR

00973690

Scanned with OKEN Scanner

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
(CIN: L24233GJ2007PLC049692)
(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)

Standalone Statement of Unaudited Financial Results for the Year ended and Half Year ended on September 30, 2026

(Rs. In Lakhs)

	6 Months ended			Year Ended	
Particulars	30/09/2026	31/03/2026	30/09/2025	31/03/2026	31/03/2025
	Unaudited	Unaudited	Unaudited	Audited	Audited
Revenue from Operations	593.89	452.50	399.15	851.65	666.87
Other Income	16.57	29.40	3.80	33.20	15.11
Total Income	610.46	481.90	402.95	884.85	681.98
Expenses					
Cost of Material Consumed	63.22	60.01	32.17	92.18	85.24
Purchases of Stock in Trade	66.94	93.66	133.81	227.47	201.11
Change in Inventories of work in progress and finished goods	97.11	6.67	(9.63)	(2.96)	(86.43)
Employee Benefit Expenses	103.20	119.30	106.66	225.96	189.52
Finance Costs	27.22	13.46	11.33	24.79	13.95
Depreciation and Amortization Expenses	66.50	51.06	30.18	81.24	37.71
Other Expenses	163.14	180.25	117.79	298.04	200.51
Total expenses	587.33	524.41	422.31	946.72	641.61
Profit/(Loss) before Exceptional and Extraordinary Item and Tax	23.13	(42.51)	(19.36)	(61.87)	40.37
Exceptional Item				-	-
Profit/(Loss) before Extraordinary Item and Tax	23.13	(42.51)	(19.36)	(61.87)	40.37
Extraordinary Item				-	-
Profit/(Loss) before Tax	23.13	(42.51)	(19.36)	(61.87)	40.37
Tax Expenses					
- Current Tax	1.64		-		11.35
- Deferred Tax	1.72	3.44	0.19	3.63	(0.74)
Profit/(Loss) after Tax	19.76	(45.95)	(19.55)	(65.50)	29.76
Earnings Per Share (Face Value per Share Rs.10 each)					
-Basic (In Rs)	0.23	(0.53)	(0.22)	(0.75)	0.68
-Diluted (In Rs)	0.23	(0.53)	(0.22)	(0.75)	0.68

See accompanying notes to the financial statements

As per our report of even date
For and on behalf of the Board of
HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

FOR, HAMPS BIO LIMITED
DIRECTOR

HERRIK SHAH
MANAGING DIRECTOR
01052316

FOR, HAMPS BIO LIMITED
DIRECTOR

SHRENIK SHAH
WHOLE TIME
00973690

Scanned with OKEN Scanner

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
(CIN: L24233GJ2007PLC049692)
(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)

Standalone statement of Unaudited Cash Flow Statement for the half year ended 30th September, 2026

(Rs. In Lakhs)

Particulars	30 September, 2026	31 March, 2026
CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit after tax	19.76	(65.49)
Profit/(loss) from Discontinuing Operation (after tax)	-	
Depreciation and Amortisation Expense	66.50	81.24
Provision for tax	1.64	
Deferred Tax	1.72	3.63
Other Adjustments		(1.09)
Interest Income	(0.97)	(3.68)
Finance Costs	27.22	24.79
Operating Profit before working capital changes	115.88	39.40
Adustment for:		
Inventories	14.41	(6.28)
Trade Receivables	(29.35)	(1.34)
Loans and Advances		1.20
Other Current Assets	5.47	(30.89)
Trade Payables	8.01	(26.65)
Other Current Liabilities	25.24	(2.06)
Short-term Provisions	1.64	(10.06)
Cash (Used in)/Generated from Operations	141.30	(36.68)
Tax paid(Net)	1.64	-
Net Cash (Used in)/Generated from Operating Activities	139.66	(36.68)
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant and Equipment	(45.36)	(321.86)
Sale of Property, Plant and Equipment	-	-
Purchase of Investments Property	-	-
Sale of Investment Property	-	-
Purchase of Equity Instruments	-	(204.00)
Proceeds from Sale of Equity Instruments	-	-
Purchase of Mutual Funds	-	-
Proceeds from Sale / Redmption of Mutual Funds	-	-
Purchase of Preference Shares	-	-
Proceeds from Sale/Redemption of Preference Shares	-	-
Subsidy Received from Gujarat Government	-	-
Proceeds from Sale/Redemption of Government or trust securities	-	-
Purchase of debentures or bonds	-	-
Proceeds from Sale/Redemption of debentures or bonds	-	-
Purchase of Other Investments	-	-
Investment in Term Deposits	-	-
Maturity of Term Deposits	-	-
Movement in other non current assets	1.27	229.31
Interest received	0.97	3.68
Dividend received	-	-
Net Cash (Used in)/Generated from Investing Activities	(43.12)	(292.87)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Share Capital	-	-
Buyback of Shares	-	-
Proceeds from Long Term Borrowings	41.85	226.99
Repayment of Long Term Borrowings	-	(53.30)
Proceeds from Short Term Borrowings	-	173.15
Repayment of Short Term Borrowings	(106.73)	(3.62)
Other inflow (outflows) of cash	-	5.00
Dividends Paid (including Dividend Distribution Tax)	-	-
Interest Paid	(27.22)	(24.78)
Net Cash (Used in)/Generated from Financing Activities	(92.10)	323.44
Net Increase/(Decrease) in Cash and Cash Equivalents	4.44	(6.12)
Opening Balance of Cash and Cash Equivalents	3.45	9.57
Exchange difference of Foreign Currency Cash and Cash equivalents	-	-
Closing Balance of Cash and Cash Equivalents	7.89	3.45

Note:
The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".

As per our report of even date
For and on behalf of the Board of
HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

FOR, HAMPS BIO LIMITED

HERRIK SHAH
MANAGING DIRECTOR
01052316
DIRECTOR

FOR, HAMPS BIO LIMITED

SHRENIK SHAH
WHOLE TIME DIRECTOR
00973690
DIRECTOR

Scanned with OKEN Scanner

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
NOTES TO STANDALONE FINANCIAL RESULTS
CIN: L24233GJ2007PLC049692

1. The aforesaid standalone unaudited financial results of M/s. Hamps Bio Limited, were reviewed by the audit committee and then approved by the board of directors in their meeting held on 06th November, 2026.

2. The results for the half year ended September 2026 are reviewed by the statutory auditor of the company in the compliance with the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

3. These financial results prepared in accordance with the recognition and measurement principals of accounting standard (AS) prescribed under section 133 of the companies act 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India.

4. The Earning Per Share (EPS) have been computed in accordance with Accounting Standard on Earning Per Share (EPS) AS-20.

5. The comparative results for the half year ended 30th September 2026 have not been audited/reviewed by the statutory auditors of the company. The management has exercised due diligence to ensure that the said comparative results provide true & fair view.

6. The figures for the half year ended March 2026 are the balancing figures between the audited figures in respect of full financial year and the figures up to half year ended September 2025.

7. Based on guiding principles given in the Accounting standard on 'Segment Reporting' (AS-17), the business segment of the Company is trading of medicines (Pharma) and of manufacturing of Freeze dried products. The details of the same is as follows:

Year ended 30th September, 2026	Pharma Products (Rs. in Lakhs)	Freeze dried Products (Rs. in Lakhs)	Total (Rs. in Lakhs)
Segment Revenue	216.22	377.67	593.89
Segment Assets	136.72	1049.10	1185.82
Segment Liabilities	15.13	26.44	41.57

Note: Segment results are not reported, as it is not possible to compute segment net profit or loss, or any other measure of segment profitability, without arbitrary allocations.
The company is engaged in the manufacturing of freeze dried products and trading of pharmaceutical products. As a result, fixed assets are allocated to the freeze dried products segment and only details of debtors and stock are included in Pharma segment.

8. The previous year figures have been regrouped/reclassified wherever necessary to correspond with the current year classification for the comparison

Scanned with OKEN Scanner

9. The Company's inventory comprises Raw Materials, Finished Goods, and Stock-in-Trade. Inventories are valued at the lower of cost or net realizable value, in accordance with applicable accounting standards and the Company's accounting policy. The Management has derived the valuation of inventory based on FIFO method and includes all costs incurred in bringing the inventories to their present location and condition.

10. The Company has fully utilised proceeds raised through its Initial Public Offering (IPO) towards the objects specified in the Prospectus, as detailed below:

Particulars	**Total Estimated Cost (Rs in Lakhs)**	**Amount Utilised up to March 31st, 2026 (Rs. In Lakhs)**	**Amount Utilised from April 26 to September 26 (Rs. In Lakhs)**
Purchase of Plant and Machinery & construction activity for FMCG division	359.00	359.00	Nil
Enhancing the visibility and awareness of the brand	50.00	50.00	Nil
General corporate purposes	151.87	151.87	Nil
Issue Expenses Paid	61.33	61.33	Nil
Total	622.20	622.20	Nil

Note: The Company had fully utilised the entire IPO proceeds amounting to ₹622.20 lakhs as on 31st March, 2026, in accordance with the objects specified in the Prospectus. Accordingly, no further utilisation of IPO proceeds was made during the half year ended 30th September, 2026.

Since the entire IPO proceeds were utilised during the previous financial year, no additional expenditure was incurred out of IPO proceeds during the half year ended 30th September, 2026.

For and on behalf of
HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
CIN: L24233GJ2007PLC049692

FOR, HAMPS BIO LIMITED
DIRECTOR

Herrik Shah
Managing Director
DIN : 01052316

FOR, HAMPS BIO LIMITED
DIRECTOR

Shrenik Shah
Whole Time Director
DIN : 00973690

Scanned with OKEN Scanner

MGHVS & ASSOCIATES
Chartered Accountants
8154912316, 9265096979
7048388605, 9737211161
802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

Independent Auditors' Review Report on Consolidated Unaudited Half Yearly Financial Results of the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To
The Board of Directors,
M/s. HAMPS BIO LIMITED

Opinion

We have reviewed the consolidated Unaudited Financial results ("the statement) of **M/s. HAMPS BIO LIMITED** (the company), its Wholly Owned Subsidiary (**HSDL INNOVATIVES PRIVATE LIMITED**), for the quarter ended September 30, 2026 and the year to date results for the period April 01, 2026 to September 30, 2026 which are included in the accompanying 'Consolidated Statement Of Unaudited Financial Results for the quarter and **Half year ended 30th September, 2026** the Consolidated Statement of Unaudited Balance Sheet as on that date and the Consolidated Statement of Unaudited Cash Flow for the half-year ended on that date (the "Statement"). The Statement is being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been digitally signed by us for identification purposes.

This statement which is the responsibility of the Holding Company's Management and has been approved by the Board of Directors AND has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 "Interim Financial Reporting" ("AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as

MGHVS & ASSOCIATES
Chartered Accountants
8154912316, 9265096979
7048388605, 9737211161
802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The statement includes the results of the following entities:

Relationship	Entity Name
Holding Company:	Hamps Bio Limited
Subsidiary Company:	HSDL Innovative Private Limited

Based on our limited review, conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

The consolidated unaudited financial results include the interim financial information of a Wholly Owned Subsidiary which have not been reviewed by their auditors, whose interim financial information reflect total assets of Rs. 93.48 lakhs and net assets of Rs. 102.43 lakhs as at September 30, 2026 and total revenue of Rs. 175.19 lakhs, total net profit after tax of Rs. 0.68 lakhs for the half year ended September 30, 2026 and for the period from April 01, 2026 to September 30, 2026, respectively, and cash flows (net) of Rs. (2.04) lakhs for the period from April 01, 2026 to September 30, 2026, as considered in the consolidated

MGHVS & ASSOCIATES
Chartered Accountants
8154912316, 9265096979
7048388605, 9737211161
802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

unaudited financial results. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For M G H V S & ASSOCIATES
Chartered Accountants

CA MUBASSIR M GODIL
(Partner)
M. No: 164503
FRN: 140555W
Place: Surat
Date: 06/11/2026
UDIN: 26164503RXWFTD2748

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

(CIN: L24233GJ2007PLC049692)

(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)

Consolidated Statement of Balance Sheet as at 30th September, 2026

Particulars	30-Sep-26	31-Mar-26
I. EQUITY AND LIABILITIES		
(1) Shareholders' funds		
(a) Share Capital	871.20	871.20
(b) Reserves and Surplus	(40.48)	(61.11)
Total	830.72	810.09
(2) Non-current liabilities		
(a) Long-term Borrowings	459.51	409.76
(b) Other Long-term Liabilities	10.34	10.21
Total	469.85	419.97
(3) Current liabilities		
(a) Short-term Borrowings	161.03	278.49
(b) Trade Payables	-	-
- Due to Micro and Small Enterprises	-	7.45
- Due to Others	44.27	26.05
(c) Other Current Liabilities	71.52	47.77
(d) Short-term Provisions	3.05	2.00
Total	279.87	361.76
Total Equity and Liabilities	**1,580.44**	**1,591.82**
II. ASSETS		
(1) Non-current assets		
(a) Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	878.04	796.04
(ii) Intangible Assets	115.55	113.78
(iii) Capital Work-in-progress	-	108.37
(iv) Intangible Assets under Development	-	-
(b) Non-current Investments	7.67	7.13
(c) Deferred Tax Assets (net)	3.87	5.25
(d) Other Non-current Assets	25.03	31.53
Total	1,030.15	1,062.10
(2) Current assets		
(a) Inventories	255.56	258.19
(b) Trade Receivables	178.58	158.52
(c) Cash and cash equivalents	19.35	16.95
(d) Short-term Loans and Advances	0.96	-
(e) Other Current Assets	95.85	96.06
Total	550.30	529.72
Total Assets	**1,580.44**	**1,591.82**

See accompanying notes to the financial statements

As per our report of even date

For and on behalf of the Board of

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

FOR, HAMPS BIO LIMITED

HERRIK SHAH
DIRECTOR
MANAGING DIRECTOR
01052316

FOR, HAMPS BIO LIMITED

SHREMIK SHAH
WHOLE TIME DIRECTOR
DIRECTOR
00973690

Scanned with OKEN Scanner

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
(CIN: L24233GJ2007PLC049692)
(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)

Consolidated Statement of Unaudited Financial Results for the Year ended and Half Year ended on September 30, 2026

Particulars	6 Months ended				Year Ended	
	30/09/2026	31/03/2026	30/09/2025	31/03/2025	31/03/2026	31/03/2025
	Unaudited	Audited	Unaudited	Audited	Audited	Audited
Revenue from Operations	730.76	448.31	399.15	312.86	847.46	666.87
Other Income	21.58	29.41	3.80	6.70	33.21	15.11
Total Income	752.34	477.72	402.95	319.56	880.67	681.98
Expenses						
Cost of Material Consumed	78.28	59.83	32.17	49.39	92.00	85.24
Purchases of Stock in Trade	66.94	93.66	133.81	97.00	227.47	201.11
Change in Inventories of work in progress and finished goods	97.11	6.60	(9.63)	(60.78)	(3.03)	(86.43)
Employee Benefit Expenses	177.52	150.21	106.66	96.72	256.87	189.52
Finance Costs	28.65	13.55	11.33	5.94	24.88	13.95
Depreciation and Amortization Expenses	75.72	51.50	30.18	18.78	81.68	37.71
Other Expenses	204.55	153.00	117.79	108.27	270.79	200.51
Total expenses	728.77	528.35	422.31	315.32	950.66	641.61
Profit/(Loss) before Exceptional and Extraordinary Item and Tax	23.57	(50.63)	(19.36)	4.24	(69.99)	40.37
Exceptional Item					-	-
Profit/(Loss) before Extraordinary Item and Tax	23.57	(50.63)	(19.36)	4.24	(69.99)	40.37
Extraordinary Item					-	-
Profit/(Loss) before Tax	23.57	(50.63)	(19.36)	4.24	(69.99)	40.37
Tax Expenses						
- Current Tax	1.75	0.40	-	1.08	0.40	11.35
- Deferred Tax	1.38	3.29	0.19	(0.11)	3.48	(0.74)
Profit/(Loss) after Tax	20.44	(54.32)	(19.55)	3.27	(73.87)	29.76
Earnings Per Share (Face Value per Share Rs.10 each)						
-Basic (In Rs)	0.23	(0.62)	(0.22)	0.08	(0.85)	0.68
-Diluted (In Rs)	0.23	(0.62)	(0.22)	0.08	(0.85)	0.68

See accompanying notes to the financial statements

As per our report of even date
For and on behalf of the Board of
HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

FOR, HAMPS BIO LIMITED

HERRIK SHAH
MANAGING DIRECTOR
01052316
DIRECTOR

FOR, HAMPS BIO LIMITED

SHRENIK SHAH
WHOLE TIME
00973690
DIRECTOR

Scanned with OKEN Scanner

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
(CIN: L24233GJ2007PLC049E92)
(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)

Consolidated statement of Unaudited Cash Flow Statement for the half year ended 30th September, 2026

Particulars	Note	30/09/2026	31/03/2026
CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit after tax		30.44	(73.87)
Profit/(loss) from Discontinuing Operation (after tax)		-	-
Depreciation and Amortisation Expense		75.72	81.68
Provision for tax		1.75	0.40
Deferred Tax		1.38	1.79
Other Adjustments		-	(1.09)
Interest Income		(5.54)	(3.68)
Finance Costs		28.65	24.88
Operating Profit before working capital changes		122.41	30.11
Adustment for:			
Inventories		2.63	(20.20)
Trade Receivables		(20.06)	(39.30)
Loans and Advances		(0.96)	1.20
Other Current Assets		0.21	(33.45)
Trade Payables		10.77	(26.75)
Other Current Liabilities		23.75	26.88
Long term Liabilities		0.13	-
Short-term Provisions		1.05	(9.38)
Cash (Used in)/Generated from Operations		139.92	(70.87)
Tax paid(Net)		1.75	0.40
Net Cash (Used in)/Generated from Operating Activities		138.17	(71.27)
CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Property, Plant and Equipment		(50.91)	(513.28)
Purchase of Other Investments		(0.54)	-
Movement in other non current assets		6.50	216.61
Interest received		5.54	3.68
Dividend received		-	-
Net Cash (Used in)/Generated from Investing Activities		(39.41)	(292.99)
CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Long Term Borrowings		49.75	260.39
Repayment of Long Term Borrowings		-	(53.30)
Proceeds from Short Term Borrowings		-	188.06
Repayment of Short Term Borrowings		(117.46)	(3.62)
Other inflow (outflows) of cash		-	5.00
Interest Paid		(28.65)	(24.88)
Net Cash (Used in)/Generated from Financing Activities		(96.36)	371.64
Net Increase/(Decrease) in Cash and Cash Equivalents		2.41	7.38
Opening Balance of Cash and Cash Equivalents		16.95	9.57
Exchange difference of Foreign Currency Cash and Cash equivalents		-	-
Closing Balance of Cash and Cash Equivalents	15	19.36	16.95

Note:
The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".
As per our report of even date
For and on behalf of the Board of
HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

FOR, HAMPS BIO LIMITED
HERRIK SHAH
MANAGING DIRECTOR
01052316
DIRECTOR

FOR, HAMPS BIO LIMITED
SHRENIK SHAH
WHOLE TIME DIRECTOR
00973690
DIRECTOR

Scanned with OKEN Scanner

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
NOTES TO CONSOLIDATED FINANCIAL RESULTS
CIN: L24233GJ2007PLC049692

1. The above consolidated unaudited Financial Results of M/s. Hamps Bio Limited (the "Parent Company") and M/s. HSDL Innovative Private Limited (the "Subsidiary") (The Company and its subsidiary together herein referred to as the "Group") Group for the half year ended 30th September, 2026 have been prepared in accordance with the recognition and measurement principles laid down in applicable Accounting Standards ("AS") as prescribed under section. 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

2. The above Unaudited Consolidated Financial Results of the Group for the year and half year ended 30th September, 2026 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on 06th November, 2026. The statutory auditors have expressed an unmodified limited review conclusion on the financial results.

3. The Earning Per Share (EPS) has been computed in accordance with Accounting Standard on Earning Per Share (EPS) AS-20.

4. Previous period figures have been regrouped/reclassified wherever necessary.

5. The accounting policies and methods of computation adopted in the preparation of these unaudited consolidated financial results are consistent with those followed in the preceding financial year.

6. During the previous financial year, the Company acquired 100% stake in M/s. HSDL Innovative Private Limited on 25th March, 2026, thereby making it a wholly owned subsidiary of the Company. Accordingly, the consolidated financial results for the half year ended 30th September, 2026 include the financial results of the subsidiary. Since FY 2025-26 was the first year of consolidation, the comparative figures for the corresponding half year ended 30th September, 2025 represent the standalone financial results of the Parent Company, as there was no subsidiary during the corresponding previous period.

7. Based on guiding principles given in the Accounting standard on 'Segment Reporting' (AS-17), the business segment of the Group is trading of medicines (Pharma) and of manufacturing of Freeze dried products. The details of the same is as follows:

Half Year ended 30th September, 2026	Pharma Products (Rs. in Lakhs)	Freeze dried Products (Rs. in Lakhs)	Total (Rs. in Lakhs)
Segment Revenue	216.22	552.86	769.08
Segment Assets	136.72	1204.05	1340.77
Segment Liabilities	15.13	36.24	51.37

Note:
**Accordingly, fixed assets are predominantly allocated to the Freeze Dried Products segment,*

Scanned with OKEN Scanner

whereas debtors and inventories relating to trading activities are considered under the Pharma Products segment.

*** The above segment information comprises figures of the Holding Company and its wholly owned subsidiary consolidated in accordance with applicable Accounting Standards.*

Segment results are not reported, as it is not possible to compute segment net profit or loss, or any other measure of segment profitability, without arbitrary allocations.

8. The Company had fully utilised the proceeds raised through its Initial Public Offering (IPO) towards the objects specified in the Prospectus as at 31st March, 2026. Accordingly, no further utilisation of IPO proceeds was made during the half year ended 30th September, 2026.

For and on behalf of
HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
CIN: L24233GJ2007PLC049692

FOR, HAMPS BIO LIMITED
DIRECTOR

Herrik Shah
Managing Director
DIN : 01052316

FOR, HAMPS BIO LIMITED
DIRECTOR

Shrenik Shah
Whole Time Director
DIN : 00973690

Scanned with OKEN Scanner